ASTM: Summary for Aastrom Biosciences, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Tuesday, November 24, 2009, 5:15am EST - Canadian Markets open in 4 hours and 15 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Aastrom Biosciences, Inc. (ASTM)

On Nov 23: 0.308 USD 0.00 (0.00%)

MORE ON ASTM

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Aastrom Biosciences, Inc. (NCM:ASTM) Delayed quote data

Last Trade:	0.308 USD
Trade Time:	Nov 23
Change:	0.00 (0.00%)
Prev Close:	0.308
Open:	N/A
Bid:	0.29 x 2500
Ask:	0.38 x 500
1y Target Est:	0.50

Day's Range:	N/A - N/A
52wk Range:	0.29 - 0.78
Volume:	0
Avg Vol (3m):	1,639,180
Market Cap:	53.58M
P/E (ttm):	N/A
EPS (ttm):	-0.105
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add ASTM to Portfolio

Download Data

HEADLINES

•	AASTROM BIOSCIENCES INC Financials
	EDGAR Online Financials (Fri, Nov 13)

•	Can Stem Cells Put an End To Paralysis?
	Indie Research (Wed, Nov 11)

•	Morningstar Strategist Says Healthcare Bill Will Be Law By End Of Year: Is Your Portfolio Ready?
	Wall Street Transcript (Mon, Nov 9)

•	AASTROM BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition
	EDGAR Online (Fri, Nov 6)

•	Stem Cell Traders Flock to Geron
	Indie Research (Fri, Oct 30)

•	AASTROM BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
	EDGAR Online (Tue, Oct 27)

•	AASTROM BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
	EDGAR Online (Tue, Oct 20)

•	Another Coin-Flip Bet on a Stem Cell Drug
	Indie Research (Fri, Oct 9)

•	Aastrom Biosciences receives delisting notice
	AP (Wed, Oct 7)

•	AASTROM BIOSCIENCES INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta
	EDGAR Online (Wed, Oct 7)

More Headlines for ASTM...

ANALYST

EPS Est (next year) (Jun-10) :	N/A
EPS Est (in 2 years) (Jun-11) :	N/A
Avg Rec (current)*:	3.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Aastrom Biosciences, Inc. engages in developing autologous cell products for the repair or regeneration of human tissue. Its proprietary tissue repair cell (TRC) technology involves the use of a patient's own cells to manufacture products to ...

Full Company Profile

Add to Portfolio

Email to a Friend

•